A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Bayer
- 24 Sep 2008 Actual end date (Sep 2008) added as reported by CT.gov
- 24 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
- 25 Jan 2008 New trial record.